Clinical Drug Experience Knowledgebase

autologous hematopoietic cell (1 trial)

autologous mononuclear stem cell (5 trials)

bendamustine (treanda) (2 trials)

bleomycin (blenoxane) (10 trials)

carboplatin (paraplatin) (2 trials)

carmustine (bicnu) (4 trials)

chlorambucil (Leukeran) (1 trial)

cisplatin (platinol) (2 trials)

cyclophosphamide (cytoxan) (23 trials)

cytarabine (cytosar-u) (6 trials)

dacarbazine (dtic-dome) (5 trials)

darbepoetin alfa (aranesp) (1 trial)

doxorubicin (Doxil) (24 trials)

epirubicin (ellence) (1 trial)

etoposide (vepesid) (11 trials)

filgrastim (neupogen) (2 trials)

fludarabine (fludara) (4 trials)

fludeoxyglucose f-18 (1 trial)

ifosfamide (ifex) (2 trials)

interferon alpha-2b (Intron-A) (4 trials)

lenalidomide (revlimid) (8 trials)

melphalan (alkeran) (4 trials)

mesna (mesnex) (1 trial)

peripheral blood hematopoietic cell (1 trial)

prednisone (meticorten) (18 trials)

procarbazine (matulane) (5 trials)

rituximab (rituxan) (27 trials)

sargramostim (leukine) (4 trials)

stem cells (1 trial)

urea (5 trials)

vinblastine (velban) (5 trials)

vincristine (oncovin) (16 trials)

vindesine (5 trials)

allogeneic adipose derived mesenchymal stem cell (1 trial)

atezolizumab (tecentriq) (1 trial)

bortezomib (velcade) (4 trials)

brentuximab vedotin (adcetris) (4 trials)

gemcitabine (gemzar) (3 trials)

glofitamab (1 trial)

ibritumomab tiuxetan (zevalin) (2 trials)

ibrutinib (imbruvica) (2 trials)

inotuzumab ozogamicin (besponsa) (1 trial)

iph4102 (1 trial)

mitoxantrone (novantrone) (1 trial)

obinutuzumab (gazyva) (3 trials)

ofatumumab (arzerra) (1 trial)

oxaliplatin (eloxatin) (3 trials)

ruxolitinib (jakafi) (1 trial)

tislelizumab (1 trial)

valemetostat (1 trial)

venetoclax (venclexta) (2 trials)

zarnestra (1 trial)